Circulating antibodies recognizing oxidatively modified low-density lipoprotein in children

Pediatric Research

Volumn 45, Issue 1, 1999, Pages 94-99

  Iughetti, Lorenzo ^a   Volta, Cecilia ^a   Maggi, Elena ^a   Palladini, Giuseppina ^a   Perugini, Cristina ^a   Bellomo, Giorgio ^a   Bernasconi, Sergio ^a  

^a Department of Paediatrics ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE; ALPHA TOCOPHEROL; ANTIBODY; ANTIOXIDANT; APOLIPOPROTEIN B100; COPPER; EPITOPE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN G; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; SERUM ALBUMIN; TRANSFERRIN;

ADOLESCENT; ADULT; ANTIGEN RECOGNITION; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID PEROXIDATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0032905706     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-199901000-00016     Document Type: Article

References (32)

1. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL 1992 Autoantibodies against oxidised LDL and progression of carotid atherosclerosis. Lancet 339:883-887
2. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, Finardi G, Bellomo G 1994 LDL oxidation in patients with severe carotid atherosclerosis: a study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14:1892-1899
3. Seccia M, Albano E, Maggi E, Bellomo G 1997 Circulating autoantibodies recognizing peroxidase-oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol 17:134-140
4. Witztum JL 1994 The oxidation hypothesis of atherosclerosis. Lancet 344:793-795
5. Lehr HA, Hubner D, Nolte B, Finckh B, Beieigel U, Kohlschutter A, Messmer K 1991 Oxidatively modified human LDL stimulates leukocyte adherence to the microvascular endothelium in vivo. Res Exp Med 191:85-90
6. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Ramshad B, Esterson M, Fogelman AM 1990 Minimally modified low-density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85:1260-1266
7. Fogelman AM, Shechter I, Saeger J, Hokom M, Child JS, Edwards PA 1980 Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A 77:2214-2218
8. Raines EW, Ross R 1993 Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 69(suppl):S30-S37
9. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler S, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL 1990 Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10:325-335
10. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler S, Parthasarathy S, Carew TE, Steinberg D, Witztum JL 1989 Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 86:1372-1376
11. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL 1994 Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet 343:645-646
12. Bellomo G, Maggi E, Palladini G, Taddei F, Seccia M, Finardi G 1995 Diagnostic criteria in investigating LDL oxidation. In: Bellomo G, Finardi G, Maggi E, Rice-Evans C (eds) Free Radicals, Lipoprotein Oxidation and Atherosclerosis. Richelieu Press, London, pp 263-286
13. Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G 1995 Presence of autoantibodies against oxidatively-rnodified low density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low density lipoprotein oxidation. J Hypertens 13:129-138
14. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G 1994 Autoantibodies against oxidatively modified LDL in uremic patients undergoing dialysis. Kidney Int 46:869-876
15. Carew TE, Schwenke DC, Steinberg D 1987 An atherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low-density lipoprotein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit. Proc Nat Acad Sci USA 84:7725-7729
16. Daugherty A, Zweifel BS, Schonfeld G 1989 Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol 98:612-618
17. Gey F 1995 Prevention of early stages of cardiovascular disease and cancer may require concurrent optimization of all major antioxidants and other nutrients. In: Bellomo G, Finardi G, Maggi E, Rice-Evans C (eds) Free Radicals, Lipoprotein Oxidation and Atherosclerosis. Richelieu Press, London, pp 53-99
18. Strong JP, McGill HC 1969 The pediatric aspects of atherosclerosis. J Atheroscler Res 9:251-265
19. Stary HC 1989 Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 9(suppl 1):1-19
20. Esterbauer H, Striegl G. Puhl H, Rotheneder M 1989 Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6:67-75
21. Giessauf A, Steiner E, Esterbauer H 1995 Early destruction of tryptophan residues of apolipoprotein B is a vitamin E-independent process during copper-mediated oxidation of LDL. Biochim Biophys Acta 1256:221-232
22. Jurgens G, Hoff HF, Chisolm GM, Esterbauer H 1987 Modification of human serum low density lipoprotein by oxidation: characterisation and pathophysiological implications. Chem Phys Lipids 45:315-336
23. Esterbauer H, Gebicki J. Puhl H, Jurgens G 1992 The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13:341-390
24. Palinski W, Ord V, Plump AS, Breslow JL, Steinberg D, Witztum JL 1994 ApoE deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 14:605-616
25. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss L, Witztum JL 1996 Cloning of monoclonal antibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. J Clin Invest 98:800-814
26. Horkko S, Miller E, Dudi E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W, Witztum JL 1996 Antiphospholipid antibodies are directed against epitopes of oxidized phospholipid: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 98:815-825
27. De Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendrix JCM, Stalenhoef AFH 1991 Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11:298-306
28. Thomas CE, Jackson RL 1991 Lipid hydroperoxide involvement in copper dependent and independent oxidation of low-density lipoproteins. J Pharmacol Exp Ther 256:1182-1188
29. Lavy A, Brook GJ, Dankner G, Amotz AB, Aviram M 1991 Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism 40:794-799
30. Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G 1995 Autoantibodies against oxidatively modified low density lipoproteins in NIDDM. Diabetes 44:60-66
31. Maggi E, Perani G, Finardi G, Franceschi C, Bellomo G 1993 LDL oxidation in aging. In: Rice-Evans C, Corongiu F (eds) Free Radicals and Antioxidants in Nutrition. Richelieu Press, London, pp 427-437
32. Stulnig TM, Jurgens G, Chen Q, Moll D, Schonitzer D, Jarosch E, Wick G 1996 Properties of low density lipoproteins relevant to oxidative modifications change paradoxically during aging. Atherosclerosis 126:85-94